Interferon-γ responses to Mycobacterium tuberculosis-specific antigens in diabetes mellitus

European Respiratory Journal

Volumn 44, Issue 3, 2014, Pages 805-808

  Gan, Suay Hong ^a   KhinMar, Kyi Win ^a   Barkham, Timothy M ^a   Koh, Chwee Kim ^a   Shen, Liang ^b   Wang, Yee Tang ^a   Chee, Cynthia B E ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; BACTERIAL ANTIGEN; DIAGNOSTIC KIT; GAMMA INTERFERON; MYCOBACTERIUM TUBERCULOSIS ANTIGENS;

ACID FAST BACTERIUM; ANTIGEN DETECTION; DIABETES MELLITUS; ETHNICITY; GLYCEMIC CONTROL; HUMAN; IMMUNE RESPONSE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LETTER; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; T LYMPHOCYTE; TUBERCULIN TEST; COMPLICATION; CYTOLOGY; DIAGNOSTIC KIT; FEMALE; IMMUNOLOGY; MALE; MICROBIOLOGY; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; SINGAPORE; TUBERCULOSIS;

ANTIGENS, BACTERIAL; DIABETES COMPLICATIONS; FEMALE; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REAGENT KITS, DIAGNOSTIC; RECURRENCE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SINGAPORE; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 84907376609     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00226613     Document Type: Letter

References (14)

1. World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes. WHO/HTM/TB/2011.15. Geneva, WHO, 2011.
2. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008; 5: e152.
3. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Medicine 2011; 9: 81.
4. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
5. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
6. Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
7. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63-75.
8. Migliori GB, Zellweger JP, Abubakar I, et al. European Union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.
9. Migliori GB, Sotgiu G, Blasi F, et al. Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). Eur Respir J 2011; 38: 493-492.
10. Goletti D, Stefania C, Butera O, et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicentre TBNET-study. PloS One 2008; 3: e3417.
11. Jafari C, Thijsen S, Sotgiu G, et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis. Am J Respir Crit Care Med 2009; 180: 666-673.
12. Chee CBE, Gan SH, Khinmar KW, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. J Clin Microbiol 2008; 46: 1935-1940.
13. Walsh MC, Camerlin AJ, Miles R, et al. The sensitivity of interferon-γ release assays is not compromised in tuberculosis patients with diabetes. Int J Tuberc Lung Dis 2011; 15: 179-184.
14. Kabeer BSA, Balambal R, Thomas A, et al. Role of QuantiFERON-TB Gold, interferon gamma inducible preotein-10 and tuberculin skin in active tuberculosis diagnosis. PloS One 2010; 5: e9051.